M. Bilal Abid, Medical Director, Blood and Marrow Transplantation and Cellular Therapy Program at Texas Tech University Health Sciences Center, shared a post on LinkedIn:
“Honored to present our institutional data
‘Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma’
So the impact of cell version on CAR-T outcomes in patients with aggressive lymphoma is unknown. If this was known, CAR-T products could potentially be tailored according to COO subtypes. We examined this impact of COO on CAR-T at MD Anderson.
Key takeaways:
- GCB subtype has a superior PFS (HR 1.4) and OS (HR 1.5) compared to non-GCB (ABC) subtype from CD19+CAR-T.
- GCB subtype derive a significant survival benefit when CAR-T is given in 3L+ setting. No difference between the 2 COO subtypes in the second line setting.
- Consistent with existing literature, CAR-T in earlier lines (2L vs 3L+) confers a PFS advantage (HR 1.65).”
More posts featuring M. Bilal Abid on OncoDaily.
